Table 1 Preoperative characteristics of patients combined with moderate aortic regurgitation .

From: Clinical outcomes and management strategies for moderate aortic regurgitation in patients undergoing rheumatic mitral valve surgery

Characteristic

Total

(N = 338)

NT

(N = 128)

AVP

(N = 91)

AVR

(N = 119)

P value

Age (y)

55.20 ± 10.71

55.14 ± 11.97

54.20 ± 10.61

56.03 ± 9.26

0.47

Female

225 (66.6)

87 (68.0)

64 (70.3)

74 (62.2)

0.42

BMI (kg/m2)

23.73 ± 3.08

23.81 ± 3.30

23.59 ± 2.90

23.75 ± 2.98

0.87

BSA (m2)

1.66 ± 0.17

1.66 ± 0.17

1.64 ± 0.17

1.67 ± 0.17

0.49

Hypertension

59 (17.5)

24 (18.8)

17 (18.7)

18 (15.1)

0.71

Diabetes mellitus

30 (8.9)

7 (5.5)

8 (8.8)

15 (12.6)

0.14

Coronary artery disease

38 (11.2)

15 (11.7)

10 (11.0)

13 (10.9)

0.98

Stroke

34 (10.1)

11 (8.6)

6 (6.6)

17 (14.3)

0.15

Chronic pulmonary disease

16 (4.7)

6 (4.7)

4 (4.4)

6 (5.0)

0.98

Atrial fibrillation

226 (66.9)

85 (65.6)

62 (68.1)

80 (67.2)

0.92

Cardiac surgery history

16 (4.8)

8 (6.2)

2 (2.2)

6 (5.1)

0.38

NYHA functional class

    

< 0.001†‡

    I-II

206 (60.9)

85 (66.4)

65 (71.4)

56 (41.1)

 

    III-IV

132 (39.1)

43 (33.6)

26 (28.6)

63 (52.9)

 

PAH

157 (46.7)

59 (46.1)

40 (44.0)

59 (49.6)

0.71

Mitral stenosis

    

0.13

    None or trace

8 (2.4)

4 (3.1)

1 (1.1)

3 (2.5)

 

    Mild

49 (14.5)

15 (11.7)

18 (19.8)

16 (13.4)

 

    Moderate

82 (24.3)

28 (21.9)

16 (17.6)

38 (31.9)

 

    Severe

199 (58.9)

81 (63.3)

56 (61.5)

62 (52.1)

 

Mitral valve area (cm2)

1.20

(0.90, 1.50)

1.10

(0.90,1.49)

1.28

(1.00,1.63)

1.18

(0.90,1.50)

0.21

Mitral regurgitation

    

0.18

    None or trace

47 (13.9)

25 (19.5)

10 (11.0)

12 (10.1)

 

    Mild

100 (29.6)

30 (23.4)

28 (30.8)

42 (35.3)

 

    Moderate

74 (21.9)

28 (21.9)

18 (19.8)

28 (23.5)

 

    Severe

117 (34.6)

45 (35.2)

35 (38.5)

37 (31.1)

 

Aortic stenosis

    

< 0.001†‡

    None or trace

244 (72.2)

107 (83.6)

71 (78.0)

66 (55.5)

 

    Mild

94 (27.8)

21 (16.4)

20 (22.0)

53 (44.5)

 

Aortic valve peak velocity (cm/s)

193.12 ± 50.72

174.93 ± 47.63

195.29 ± 46.92

212.23 ± 50.02

< 0.001*†‡

Aortic valve calcification

131 (39.5)

33 (25.8)

31 (34.1)

67 (59.3)

< 0.001†‡

Regurgitation area of aortic valve (cm2)

5.44 ± 1.27

4.96 ± 1.21

5.43 ± 1.29

5.84 ± 1.19

0.001*†

VCW of aortic valve (mm)

4.16 ± 0.81

3.85 ± 0.66

4.24 ± 0.85

4.46 ± 0.81

< 0.001*†

Tricuspid regurgitation

    

0.83

    None or trace

23 (6.8)

7 (5.5)

6 (6.6)

10 (8.4)

 

    Mild

141 (41.7)

56 (43.8)

36 (39.6)

49 (41.2)

 

    Moderate

104 (30.8)

35 (27.3)

32 (35.2)

37 (31.1)

 

    Severe

70 (20.7)

30 (23.4)

17 (18.7)

23 (19.3)

 

LVEDD (mm)

49.34 ± 5.78

48.08 ± 5.25

49.57 ± 5.66

50.56 ± 6.19

0.003*†

LVESD (mm)

33.30 ± 5.46

32.30 ± 4.77

33.74 ± 5.70

34.10 ± 5.84

0.02*†

LVEF (%)

59.72 ± 7.10

59.60 ± 7.03

59.91 ± 6.84

59.71 ± 7.41

0.95

Left atrial (mm)

50.38 ± 8.52

50.51 ± 7.85

50.30 ± 9.36

50.29 ± 8.63

0.98

Combined surgery

Ablation

224 (66.3)

84 (65.6)

63 (69.2)

77 (64.7)

0.78

Thrombectomy

25 (7.4)

6 (4.7)

10 (11.0)

9 (7.6)

0.21

CABG

18 (5.3)

6 (4.7)

6 (6.6)

6 (5.0)

0.81

Tricuspid surgery

315 (93.2)

121 (94.5)

85 (93.4)

109 (91.6)

0.66

Mitral valve surgery

Mitral valve repair

223 (66.0)

96 (75.0)

76 (83.5)

51 (42.9)

< 0.001†‡

Mechanical valve

72 (21.3)

16 (12.5)

11 (12.1)

45 (37.8)

< 0.001†‡

Biological valve

43 (12.7)

16 (12.5)

4 (4.4)

23 (19.3)

0.01

  1. Values are mean ± standard deviation; n (%); and median (interquartile range). NT, non-surgical treatment; AVP, aortic valvuloplasty; AVR, aortic valve replacement; BMI, body mass index; BSA, body surface area; NYHA, New York Heart Association; PAH, pulmonary artery hypertension; VCW, vena contracta width; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; *. Indicates a statistically significant difference between the NT and AVP groups; . Indicates a statistically significant difference between the NT and AVR groups; . Indicates a statistically significant difference between the AVP and AVR groups.